Clinical trials
Nasopharyngeal Neoplasms trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 35 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 17 |
| Zhejiang Cancer Hospital | 3 |
| Hospital Authority, Hong Kong | 2 |
| Yun-fei Xia | 2 |
| Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 1 |
| Biotech Pharmaceutical Co., Ltd. | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| China International Medical Foundation | 1 |
| Fudan University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nasopharyngeal Neoplasms | 35 |
| Nasopharyngeal Carcinoma | 13 |
| Stomatitis | 3 |
| Head and Neck Neoplasms | 2 |
| Liver Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Nasopharyngeal Diseases | 2 |
| Acute Coronary Syndrome | 1 |
| Bone Marrow Diseases | 1 |
| Breast Neoplasms | 1 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.